FDA and CDC Issue Statement Concerning Rumors About Recalled Lot of Influenza Vaccine

Article

WASHINGTON, D.C. and ATLANTA -- Rumors have been circulating that report a "contaminated" lot of flu vaccine has been recalled by the FDA. This is false, the FDA states, as no contamination of any flu vaccine has been identified anywhere in the U.S. and the FDA has not recalled any lot of flu vaccine.

As with any vaccine, flu vaccine is capable of causing some side effects, these are very rarely severe. Most side effects from flu vaccine are mild such as arm soreness, redness or swelling where the shot was given, fever, or achiness. More serious reactions to the flu vaccine do occur, but they are rare.

While the FDA and the Centers for Disease Control and Prevention (CDC) are currently investigating several recent reports of possible significant allergic reactions to flu vaccine, it is important to note that the number and type of reactions reported to date are not unexpected. The reactions reported, not all of which may have been caused by the administration of vaccine, do not, at this time, suggest any problem with the flu vaccine. However, FDA and CDC will continue to investigate these and any other reports and will provide any further information as available. While serious reactions to flu vaccine are rare, each year about 114,000 people in the U.S. are hospitalized and about 36,000 people die because of the flu. The flu vaccine is the best way a person can protect themselves and their loved ones against influenza. October and November are the best months to get vaccinated; however, vaccination in December or later still provides considerable protection.

Source: FDA

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.